Akoya Biosciences Q1 2024 Adj EPS $(0.39) Misses $(0.29) Estimate, Sales $18.350M Miss $24.281M Estimate
Portfolio Pulse from Benzinga Newsdesk
Akoya Biosciences (NASDAQ:AKYA) reported Q1 2024 adjusted EPS of $(0.39), missing the $(0.29) estimate, with sales of $18.350M also missing the $24.281M estimate, marking a 14.29% decrease from the same period last year.
May 13, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Akoya Biosciences reported a significant miss in both EPS and sales for Q1 2024, with a notable year-over-year decrease in sales.
Missing both EPS and sales estimates significantly, especially by 34.48% for EPS and 24.43% for sales, indicates underperformance that could lead to negative investor sentiment and a potential decrease in stock price in the short term. The year-over-year sales decrease further compounds the negative outlook, suggesting a trend that could worry investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100